Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882505 | 0.91 | ALDH1A1 (0.39) | KDM4ERAB9AHDAC1HDAC6F2 | |
| SCHEMBL4888480 | 0.78 | AOC3 (0.53) | RAB9AAOC3MAOBKMT2A | |
| SCHEMBL4890448 | 0.78 | AOC3 (0.35) | HDAC1HDAC6AOC3MAOBMAPT | |
| SCHEMBL4883619 | 0.78 | AOC3 (0.35) | HDAC1HDAC6AOC3MAOBMAPT | |
| SCHEMBL4887311 | 0.74 | MAPT (0.42) | KDM4ERAB9AHDAC1HDAC6AOC3 | |
| SCHEMBL13024417 | 0.71 | KDM4E (0.55) | KDM4ELMNARAB9AHDAC1HDAC6 | |
| SCHEMBL12952251 | 0.69 | SLC6A3 (0.34) | KDM4ELMNARAB9AHDAC1HDAC6 | |
| SCHEMBL4882620 | 0.68 | AOC3 (0.55) | RAB9AAOC3MAOBKMT2A | |
| Hydrochloric Acid SCHEMBL4886663 | 0.67 | AOC3 (0.54) | RAB9AAOC3MAOBKMT2A | |
| SCHEMBL4889944 | 0.66 | AOC3 (0.48) | LMNARAB9AAOC3MAOBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | KDM4E 3463/4885LMNA 2418/4885RAB9A 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.